Skip to main content
新赣江 logo

新赣江 — Investor Relations & Filings

Ticker · 920367 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2024-04-01 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920367

About 新赣江

http://www.xgjyy.com/

Jiangxi Xinganjiang Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company's portfolio encompasses chemical active pharmaceutical ingredients (APIs), chemical drug preparations, and traditional Chinese medicine (TCM) formulations. Its core product offerings target therapeutic areas such as cardiovascular and cerebrovascular health, digestive system disorders, and nutritional supplementation. Key products include Ginkgo Biloba extract, Vitamin C, and various gastrointestinal medications. By maintaining an integrated value chain that spans from raw material synthesis to finished dosage forms, the company ensures quality control and supply chain efficiency. It focuses on delivering high-quality healthcare solutions through continuous innovation in pharmaceutical manufacturing and formulation technology.

Recent filings

Filing Released Lang Actions
2023年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023年度募集资金存放与实际使用情况的专项报告" which translates to "2023 Annual Special Report on the Deposit and Actual Use of Raised Funds." It details the amount of funds raised through stock issuance, the timing of fund receipt, the use of these funds, storage in special accounts, and compliance with regulatory requirements. It includes detailed financial figures related to fundraising, usage, and management of the funds, as well as auditor and sponsor opinions verifying the proper use of the funds. The document is a comprehensive report on the use and management of capital raised by the company, not just an announcement or a brief summary. It is not an annual report (10-K), nor an earnings release, nor a proxy statement, but a specialized report focused on capital raising and usage. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes. The document length (8424 characters) and detailed content confirm it is a full report, not just an announcement. Therefore, the correct classification is CAP with high confidence.
2024-04-01 Chinese
2023年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as a "2023 年度报告摘要" which translates to "2023 Annual Report Summary". It contains detailed financial data for the year 2023, including assets, net profit, earnings per share, shareholder structure, and other comprehensive business and financial information. The document references an audit report with an unqualified opinion, typical for annual reports. The length of the document (6151 characters) and the detailed financial and operational data indicate this is the actual annual report summary, not just an announcement or a brief summary. Therefore, it fits the definition of an Annual Report (10-K). FY 2023
2024-04-01 Chinese
第二届董事会第二十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It includes information about the meeting date, attendance, and voting results on various agenda items such as approval of the 2023 annual report, audit report, financial budget, profit distribution plan, and other corporate matters. The document references other filings and announcements made on the Beijing Stock Exchange information disclosure platform but does not itself contain the full annual report or audit report. It is a formal board meeting resolution announcement, which fits the category of Board/Management Information (MANG).
2024-04-01 Chinese
第二届监事会第十九次会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Jiangxi New Ganjiang Pharmaceutical Co., Ltd. It details the meeting date, attendance, and voting results on several agenda items, including approval of the 2023 Annual Report, Supervisory Board Work Report, profit distribution plan, special report on raised funds usage, and proposed deregistration of subsidiaries. The document references other filings where the full reports are disclosed on the Beijing Stock Exchange information platform, indicating this document itself is a meeting resolution announcement rather than the full reports. The document length is short (1702 characters) and it mainly announces meeting decisions and voting results. This fits best with the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports official voting outcomes from a board meeting. It is not the full Annual Report (10-K), nor a proxy solicitation or management report. Therefore, the classification is DVA with high confidence.
2024-04-01 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is titled '江西新赣江药业股份有限公司2023 年年度报告' which translates to 'Jiangxi Xinganjiang Pharmaceutical Co., Ltd. 2023 Annual Report'. It contains detailed sections including company overview, financial data, management discussion and analysis, major events, shareholder information, financing and profit distribution, board and senior management details, industry information, corporate governance, and full financial accounting reports. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes audited financial data, management's discussion and analysis, and detailed accounting data, which are typical components of an official annual report. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2024-04-01 Chinese
董事会对独立董事独立性情况的专项意见
Governance Information Classification · 95% confidence The document is a special opinion from the board regarding the independence of the company's independent directors. It references compliance with regulations and company bylaws about independent directors' independence. The content is a formal announcement about governance and director independence, not a financial report, earnings release, or management discussion. It does not contain financial data or results, nor is it a meeting presentation or voting result. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2024-04-01 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.